The size of global sepsis diagnostics market in terms of revenue was estimated to be worth $634 million in 2024 and is poised to reach $890 million by 2029, growing at a CAGR of 7.0% from 2024 to 2029.
Factors such the commercialization and availability of a wide variety of approved sepsis diagnostic devices, rising prevalence of sepsis, incidence of hospital-acquired infections, growing number of surgical procedures and increasing geriatric population are high growth prospects for the sepsis diagnostics market during the forecast period.
The molecular diagnostics segment is to register a significant growth rate over the forecast period of 2024-2029.
Based on the technology, over the forecast period of 2024-2029, the molecular diagnostics segment is to register a significant growth rate. The sepsis diagnostics product market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. The molecular diagnostics segment comprises PCR, microarray, peptide nucleic acid fluorescent in situ hybridization and DNA sequencing. The key factors encouraging the growth of mesh segment during the forecast period are the the growing need for early disease diagnosis and various advantages offered by this technique as compared others.
The hospitals & speciality clinics segment accounted for the largest share of sepsis diagnostics market in 2024-2029.
Based on end user, the hospitals & speciality clinics segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Increasing number of patients hospitalized with sepsis, in-house hospital laboratories perform a large number of blood culture tests to identify the blood stream infections (BSIs caused by bacteria, fungi/yeast, or viruses) and high prevalence of sepsis coupled with a large number of fatalities caused by the illness lead to a large share of the segment.
Asia Pacific registered the highest CAGR in the market during the forecast period.
In 2024, Asia Pacific is expected to register the highest CAGR in the market for sepsis diagnostics during the forecast period. Asia Pacific comprises China, India, South Korea, Taiwan, and Singapore, and the rest of Asia Pacific. Factors such as the growing adoption of advanced treatment options, presence of a large target patient population and improving diagnosis and treatment rates are driving the growth of the APAC sepsis diagnostics market during the forecast period.
As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
https://www.marketsandmarkets.com/Market-Reports/sepsis-diagnostic-market-92673155.html